Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5
Released On
March 13, 2023
Expires On
March 12, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Lymphoma, Oncology
This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of recent data supporting the potential utility of circulating tumor DNA to predict risk and inform personalized therapeutic decision making for patients with lymphoma.
Learning Objective
Upon completion of this activity, participants should be better able to:
- Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL)
Faculty
Mark Roschewski, MD
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD
Mark Roschewski, MD, is the clinical director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research, National Cancer Institute (NCI) in Bethesda, MD. Dr Roschewski received his medical degree from the University of Nebraska Medical Center in Omaha, NE. He completed his internship and residency in internal medicine at Eisenhower Army Medical Center in Augusta, GA and his hematology/oncology fellowship in medical oncology at the Walter Reed Army Medical Center in Washington, DC. Dr Roschewski is board certified in internal medicine.
Dr Roschewski and his research team’s focus is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, EBV-associated lymphomas, and CNS lymphomas. Recent studies from the internationally acclaimed translational research team at NCI have demonstrated highly effective therapy for subtypes of DLBCL, such as primary mediastinal B-cell lymphoma and Burkitt lymphoma. In addition, this group has demonstrated the effectiveness of targeted therapies, including inhibitors of Bruton tyrosine kinase (Btk), ibrutinib, and calabrutinib. In addition, his clinical team collaborates to develop circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in DLBCL and other lymphoma subtypes. Dr Roschewski is the principal investigator on 8 active clinical trials and associate investigator on another 5 ongoing clinical trials at NCI.
Dr Roschewski is frequently invited to give presentations on his research to both national and international audiences and has published in high-impact scientific journals. He is often a reviewer for various scientific journals, including Haematologica, Blood, Leukemia, New England Journal of Medicine, and Journal of Clinical Oncology. In addition to his research activities, Dr Roschewski is active in education and mentoring. He is an adjunct professor of medicine at the Uniformed Services University Health Sciences.
Q&A Panel
Helen E. Heslop, MD, DSc (Hon) (Chair)
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Katherine Donovan, PhD
Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Soheil Meshinchi, MD, PhD
Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA
Mark Roschewski, MD
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Katherine Donovan, PhD, has relevant financial relationships with Kronos Bio, Neomorph Inc. (Consultant); Neomorph Inc. (Speaker/Speaker’s Bureau).
Helen E. Heslop, MD, DSc, has relevant financial relationships with Allovir, Kiadis, Marker Therapeutics (Stockholder); Ankarys Therapeutics, Fresh Wind Biotechnologies, Gilead Biosciences, GSK, Immunai, Millennium, Novartis, Tessa Therapeutics (Advisor); Kuur Therapeutics, Tessa Therapeutics (Grant/Research Support).
Soheil Meshinchi, MD, PhD, has no relevant financial relationship(s) with ineligible companies to disclose.
Mark Roschewski, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Participation and Credit
In order to receive credit, users must:
- Read the learning objectives and faculty disclosure
- Participate in the activity
- Complete the activity evaluation
A statement of credit will be available to print immediately.
There is no fee to participate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
If you have questions about this activity, please contact RMEI at contact@rmei.com.